Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Functional Genomic Investigation of the Estrogen-Related Receptor Alpha Regulatory Networks in Breast Cancer Models

FY 2009-10

Summary
Breast cancer is a disease leading to various types of tumors. The differences between breast tumors link them to different risk factors and cause them to respond differently to treatments. For example, some patients with tumors that express the estrogen hormone receptor (ERalpha) efficiently respond to hormonal treatments such as tamoxifen while patients with tumors that lacking ERalpha, fail to respond and require different treatments. In order to develop targeted therapies, it is important to identify additional factors involved in dictating the diversity of the disease. Previous studies have indicated that a protein called estrogen related receptor alpha (ERRalpha) is important in promoting breast cancer development. The ERRalpha is highly similar to the ERalpha. Our initial studies have shown that ERRalpha controls the expression of breast cancer genes that are important in recurrent and metastatic tumors. We showed that ERRalpha and ERalpha regulate the expression of some common genes in breast cancer. The objectives of the present proposal are therefore to extend this analysis by addressing the following questions: 1) How do the genes regulated by ERRalpha affect ERalpha action in breast cancer cells? 2) Are the genes regulated by ERRalpha in breast cancer involved in tumor metastasis? 3) What are the molecular mechanisms utilized by ERRalpha to activate target genes expression in breast cancer cells? Although the research described therein focuses on fundamental understanding of mechanisms involved in breast tumor development, it is intended to lead to applicable results for patient care. While ERRalpha activity is not modulated by natural ligand, it can be targeted by synthetic molecules, making ERRalpha a potential therapeutic target. The comprehensive analysis of the networks of genes that are regulated by ERRalpha in different types of breast cancer will dictate future clinical research.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
206105
Name
Deblois Genevieve
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Functional Genomic Investigation of the Estrogen-Related Receptor Alpha Regulatory Networks in Breast Cancer Models
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Chromatin Immunoprecipitation (Chip)-Sequencing; Erbb2; Estrogen Receptor; Estrogen Related Receptor; Genomics; Metabolism; Nuclear Receptors; Peroxisome Proliferator-Activated Receptor-Coactivator(Pgc1); Transcription
Abstract
Breast cancer is a disease leading to various types of tumors. The differences between breast tumors link them to different risk factors and cause them to respond differently to treatments. For example, some patients with tumors that express the estrogen hormone receptor (ERalpha) efficiently respond to hormonal treatments such as tamoxifen while patients with tumors that lacking ERalpha, fail to respond and require different treatments. In order to develop targeted therapies, it is important to identify additional factors involved in dictating the diversity of the disease. Previous studies have indicated that a protein called estrogen related receptor alpha (ERRalpha) is important in promoting breast cancer development. The ERRalpha is highly similar to the ERalpha. Our initial studies have shown that ERRalpha controls the expression of breast cancer genes that are important in recurrent and metastatic tumors. We showed that ERRalpha and ERalpha regulate the expression of some common genes in breast cancer. The objectives of the present proposal are therefore to extend this analysis by addressing the following questions: 1) How do the genes regulated by ERRalpha affect ERalpha action in breast cancer cells? 2) Are the genes regulated by ERRalpha in breast cancer involved in tumor metastasis? 3) What are the molecular mechanisms utilized by ERRalpha to activate target genes expression in breast cancer cells? Although the research described therein focuses on fundamental understanding of mechanisms involved in breast tumor development, it is intended to lead to applicable results for patient care. While ERRalpha activity is not modulated by natural ligand, it can be targeted by synthetic molecules, making ERRalpha a potential therapeutic target. The comprehensive analysis of the networks of genes that are regulated by ERRalpha in different types of breast cancer will dictate future clinical research.
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Deblois, Genevieve
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2009-10) | Canada Spends